J Rio

Summary

Affiliation: Hospital Universitari Vall d'Hebron
Country: Spain

Publications

  1. doi request reprint Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response
    J Rio
    Hospital Universitari Vall d Hebron Barcelona Spain
    Eur J Neurol 19:899-904. 2012
  2. ncbi request reprint Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 11:306-9. 2005
  3. doi request reprint Measures in the first year of therapy predict the response to interferon beta in MS
    J Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Mult Scler 15:848-53. 2009
  4. doi request reprint Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients
    J Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Mult Scler 14:479-84. 2008
  5. ncbi request reprint Interferon beta in secondary progressive multiple sclerosis : daily clinical practice
    Jordi Rio
    2a planta EUI, Unitat de Neuroimmunología Clínica Hospital Universitario Vall d Hebron, Psg Vall d Hebron 119 120, 08035 Barcelona, Spain
    J Neurol 254:849-53. 2007
  6. ncbi request reprint [Natalizumab in multiple sclerosis]
    J Río-Izquierdo
    Centre d esclerosi multiple de Catalunya, Hospital Universitari Vall d Hebron, Barcelona, Espana
    Rev Neurol 49:265-9. 2009
  7. ncbi request reprint Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients
    Jordi Rio
    2TM planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 59:344-52. 2006
  8. ncbi request reprint Interferon-beta 1b in the treatment of multiple sclerosis
    Jordi Rio
    Clinical Neuroimmunology Unit, Vall d Hebron University Hospital, 08035 Barcelona, Spain
    Expert Opin Pharmacother 6:2877-86. 2005
  9. ncbi request reprint Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre
    Jordi Rio
    2a planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Psg Vall d Hebron 119 120, 08035, Barcelona, Spain
    J Neurol 252:795-800. 2005
  10. ncbi request reprint [Long-term effect of neutralizing antibodies to interferon beta-1 b in patients with multiple sclerosis]
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Med Clin (Barc) 124:140-1. 2005

Collaborators

Detail Information

Publications48

  1. doi request reprint Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response
    J Rio
    Hospital Universitari Vall d Hebron Barcelona Spain
    Eur J Neurol 19:899-904. 2012
    ..Therapy switch in patients with MS can be a strategy after a treatment failure. We studied the change in clinical activity after switching of first-line DMD because of a treatment failure...
  2. ncbi request reprint Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 11:306-9. 2005
    ....
  3. doi request reprint Measures in the first year of therapy predict the response to interferon beta in MS
    J Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Mult Scler 15:848-53. 2009
    ..Hence, the aim of this study was to investigate magnetic resonance imaging (MRI) and clinical predictors of response during the first 12 months of therapy...
  4. doi request reprint Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients
    J Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Mult Scler 14:479-84. 2008
    ....
  5. ncbi request reprint Interferon beta in secondary progressive multiple sclerosis : daily clinical practice
    Jordi Rio
    2a planta EUI, Unitat de Neuroimmunología Clínica Hospital Universitario Vall d Hebron, Psg Vall d Hebron 119 120, 08035 Barcelona, Spain
    J Neurol 254:849-53. 2007
    ..We present the data from a cohort of secondary progressive multiple sclerosis (SPMS) patients treated with interferon beta (IFNbeta-1b) at our MS clinic...
  6. ncbi request reprint [Natalizumab in multiple sclerosis]
    J Río-Izquierdo
    Centre d esclerosi multiple de Catalunya, Hospital Universitari Vall d Hebron, Barcelona, Espana
    Rev Neurol 49:265-9. 2009
    ..Natalizumab is well tolerated, although severe side effects have been reported that have conditioned its use as a second-line drug for the treatment of multiple sclerosis in patients who do not respond to conventional immunomodulators...
  7. ncbi request reprint Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients
    Jordi Rio
    2TM planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 59:344-52. 2006
    ..Early identification of nonresponder patients is crucial to try different therapeutic approaches. We investigated various criteria of treatment response to assess which criterion better identifies patients with a poor response...
  8. ncbi request reprint Interferon-beta 1b in the treatment of multiple sclerosis
    Jordi Rio
    Clinical Neuroimmunology Unit, Vall d Hebron University Hospital, 08035 Barcelona, Spain
    Expert Opin Pharmacother 6:2877-86. 2005
    ..In the face of a proportion of RRMS patients experiencing a poor response to the drug, other therapeutic approaches need to be considered...
  9. ncbi request reprint Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre
    Jordi Rio
    2a planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Psg Vall d Hebron 119 120, 08035, Barcelona, Spain
    J Neurol 252:795-800. 2005
    ..We present the data of our cohort of relapsing-remitting multiple sclerosis (RRMS) patients treated with interferon beta (IFNbeta)...
  10. ncbi request reprint [Long-term effect of neutralizing antibodies to interferon beta-1 b in patients with multiple sclerosis]
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Med Clin (Barc) 124:140-1. 2005
    ..Our goal was to evaluate the relation between the presence of neutralizing antibodies (NABs) to interferon beta-1b in multiple sclerosis (MS) patients and the clinical evolution in the following years...
  11. doi request reprint Multiple sclerosis: current treatment algorithms
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Centre d esclerosi multiple de Catalunya, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Curr Opin Neurol 24:230-7. 2011
    ..Currently, there are different formulations approved for MS treatment and others are in different stages of investigation or awaiting approval by federal agencies...
  12. ncbi request reprint Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial
    J Rio
    Centres H Vall d Hebron, Barcelona, Spain
    Neurology 63:525-8. 2004
    ..To compare the efficacy of acetaminophen, ibuprofen, and prednisone in the treatment of interferon beta-1a (IFNbeta-1a) flu-like syndrome (FLS)...
  13. ncbi request reprint Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
    M Tintore
    Unit of Clinical Neuroimmunology, Department of Neurology, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Neurology 70:1079-83. 2008
    ..To evaluate whether oligoclonal bands (OB) add information to MRI in predicting both a second attack and development of disability in patients with clinically isolated syndromes (CIS)...
  14. ncbi request reprint Neuromyelitis optica diagnosis in clinically isolated syndromes suggestive of multiple sclerosis
    M Rubiera
    Unitat de Neuroinmunologia Clínica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Neurology 66:1568-70. 2006
    ..2%) patients fulfilled NMO absolute criteria at some time and 1 (0.3%) also fulfilled one major supportive criterion. Therefore, even by systematically applying NMO criteria in patients with CIS, NMO diagnosis is reached infrequently...
  15. doi request reprint A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
    X Montalban
    Unitat de Neuroimmunologia Clinica, Multiple Sclerosis Centre of Catalonia CEM Cat, Barcelona, Spain
    Mult Scler 15:1195-205. 2009
    ..Positive effects of interferon beta on secondary clinical and magnetic resonance imaging outcomes were observed, but a beneficial effect on Expanded Disability Status Scale progression was not demonstrated...
  16. doi request reprint Brainstem lesions in clinically isolated syndromes
    M Tintore
    Unitat de Neuroimmunologia Clinica UNIC, Edif Escola d Infermeria Planta 2, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Neurology 75:1933-8. 2010
    ..Number of baseline lesions has been shown to predict future attacks and disability in clinically isolated syndromes (CIS)...
  17. doi request reprint Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?
    R Pelayo
    Multiple Sclerosis Center of Catalonia, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mult Scler 16:55-61. 2010
    ..However, the utility of MMEPs is limited by the low percentage of CIS patients having the three abnormal at baseline...
  18. ncbi request reprint Baseline MRI predicts future attacks and disability in clinically isolated syndromes
    M Tintore
    Unit of Clinical Neuroimmunology Department of Neurology, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    Neurology 67:968-72. 2006
    ..To determine the relation between baseline MRI and both conversion to multiple sclerosis (MS) and development of disability in a cohort of patients with clinically isolated syndromes (CIS)...
  19. ncbi request reprint Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort
    R Pelayo
    Department of Neurology, Unit of Clinical Neuroinmunology, Hospital Universitari Vall d Hebron, Universitat Autonoma UAB, Barcelona, Spain
    Mult Scler 13:731-6. 2007
    ..There are differences between several studies in the definition, and, therefore, the prevalence of these so-called atypical CIS. Consensus on the denomination and definition of these syndromes must be reached...
  20. ncbi request reprint An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis
    A Horga
    Centre d esclerosi multiple de Catalunya, Barcelona, Espana
    Rev Neurol 52:321-30. 2011
    ..To analyse the safety and effectiveness of natalizumab in the treatment of multiple sclerosis in a real clinical practice setting and according to the approved indications...
  21. doi request reprint Very early scans for demonstrating dissemination in time in multiple sclerosis
    C Tur
    Clinical Neuroimmunology Unit, Vall d Hebron University Hospital, Barcelona, Spain
    Mult Scler 14:631-5. 2008
    ....
  22. doi request reprint Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS
    Jaume Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, MS Centre of Catalonia, Hospital Universitari Vall d Hebron, EUI 2a planta, Passeig de la Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Neurol 257:742-6. 2010
    ..Results indicate that diplopia, facial sensory symptoms and gait disturbance occur in more than 30% of patients with CISB. Facial sensory symptoms are less associated with conversion to CDMS...
  23. doi request reprint Value of NMO-IgG determination at the time of presentation as CIS
    C Costa
    Unitat de Neuroimmunologia Clinica UNIC, Centre d Esclerosi Mu ltiple de Catalunya, Vall d Hebron Institut de Recerca, Barcelona, Spain
    Neurology 78:1608-11. 2012
    ..Despite the availability of diagnostic criteria, an overlap between neuromyelitis optica (NMO) and multiple sclerosis (MS) exists, particularly in the early stage of the disease...
  24. doi request reprint A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis
    M Comabella
    Unitat de Neuroimmunologia Clinica, CEM Cat Edif EUI 2 feminine planta, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Brain 132:3353-65. 2009
    ....
  25. ncbi request reprint [Acute disseminated encephalomyelitis: study of factors involved in a possible development towards multiple sclerosis]
    C Tur
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona
    Neurologia 23:546-54. 2008
    ..Our work supports that also observed in recent publications: that both conversion to MS or presence of sequelae after an episode of ADEM are more frequent than traditionally considered...
  26. doi request reprint Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, Edif EUI 2a planta, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035, Barcelona, Spain
    J Neurol 255:1136-41. 2008
    ....
  27. ncbi request reprint Long-term emotional state of multiple sclerosis patients treated with interferon beta
    J Porcel
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vail d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Mult Scler 12:802-7. 2006
    ..To assess the long-term emotional state of multiple sclerosis (MS) patients treated with interferon beta (IFNbeta) for at least four years...
  28. ncbi request reprint Fatigue in multiple sclerosis persists over time: a longitudinal study
    N Tellez
    2a planta EUI Unitat de Neuroimmunología, Clínica Hospital, Universitari Vall d Hebron Ps, Vall d Hebron 119 120, 08035, Barcelona, Spain
    J Neurol 253:1466-70. 2006
    ..The aim of our study was to investigate changes in fatigue in a large cohort of MS patients and to determine the relationship between changes in disability and depression with changes in fatigue severity...
  29. ncbi request reprint New diagnostic criteria for multiple sclerosis: application in first demyelinating episode
    M Tintore
    Clinical Neuroimmunology Unit, Department of Neurology, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Neurology 60:27-30. 2003
    ....
  30. doi request reprint Clinical impact of early brain atrophy in clinically isolated syndromes
    F Perez-Miralles
    Multiple Sclerosis Center of Catalonia Cemcat, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 19:1878-86. 2013
    ..The impact of global and tissue-specific brain atrophy on conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS) is not fully gauged...
  31. doi request reprint Plasma levels of 15d-PGJ are not altered in multiple sclerosis
    M Comabella
    Unitat de Neuroimmunologia Clinica, CEM Cat, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Eur J Neurol 16:1197-201. 2009
    ..The 15-deoxi delta prostaglandin J(2) (15d-PGJ(2)) is a peroxisome proliferator-activated receptor-gamma agonist with potent anti-inflammatory properties. It has been suggested that 15d-PGJ(2) may modulate multiple sclerosis (MS)...
  32. ncbi request reprint The basal ganglia: a substrate for fatigue in multiple sclerosis
    N Tellez
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035, Barcelona, Spain
    Neuroradiology 50:17-23. 2008
    ..We aimed to study the relationship between fatigue in MS and the presence of focal dysfunction in the basal ganglia and frontal white matter...
  33. ncbi request reprint [Primary progressive multiple sclerosis]
    L Brieva
    Unidad de Neuroinmulogía Clínica Hospital de la Vall d Hebron, Barcelona, Espana
    Rev Neurol 35:1074-80. 2002
    ..Finally we comment on the few therapeutic options currently available for these patients and their future prospects...
  34. doi request reprint HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis
    M Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Departament de Medicina, Universitat Autonoma de Barcelona corrected Barcelona, Spain
    J Neuroimmunol 210:116-9. 2009
    ..These findings do not support a role of the HLA class I and class II genes as modifiers of the response to IFNbeta...
  35. ncbi request reprint Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?
    N Tellez
    Unitat de Neuroimmunologia Clinica, Edif EUI, Planta 2, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, 08035 Barcelona, Spain
    Mult Scler 11:198-202. 2005
    ..As a symptom of multiple sclerosis (MS), fatigue is difficult to manage because of its unknown etiology, the lack of efficacy of the drugs tested to date and the absence of consensus about which would be the ideal measure to assess fatigue...
  36. ncbi request reprint Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b
    C Borras
    Unit of Clinical Neuroimmunology, Hospital Vall d Hebron, Barcelona, Spain
    Neurology 52:1636-9. 1999
    ..Depression has been cited as a possible side effect of interferon beta-1b (IFNbeta-1b) therapy in patients with MS. This association remains unproven because of a lack of longitudinal studies...
  37. ncbi request reprint Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis
    I Pericot
    Unitat de Neuroimmunologia Clinica, Escola d enfermeria, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 9:256-9. 2003
    ..The relationship between multiple sclerosis (MS) and Sjögren syndrome (SS) is controversial. Nine patients, previously diagnosed with primary progressive MS (PPMS) and who fulfilled the diagnostic criteria for SS, are described...
  38. doi request reprint Plasma chitotriosidase activity in multiple sclerosis
    M Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Clin Immunol 131:216-22. 2009
    ..Although these findings suggest a role of Chit in MS, our data do not support an association between plasma Chit activity and MS clinical course and clinical response to IFNbeta treatment...
  39. ncbi request reprint Can we predict flu-like symptoms in patients with multiple sclerosis treated with interferon-beta?
    X Montalban
    Unitat de Neuroimmunologia Clinica, Servei de Neurologia, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    J Neurol 247:259-62. 2000
    ..In vitro stimulation of peripheral blood leukocytes with interferon-beta1b before the beginning of therapy shows that patients who develop fever generally have increased levels of interleukin-6...
  40. doi request reprint Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon-β treatment
    S Malhotra
    Servei de Neurologia Neuroimmunologia, Centre d esclerosi múltiple de Catalunya CEM Cat, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Eur J Neurol 20:1390-7. 2013
    ....
  41. pmc Cellular immune responses in multiple sclerosis patients treated with interferon-beta
    M F Bustamante
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Exp Immunol 171:243-6. 2013
    ..These findings do not support differential cellular immune responses in PBMC at baseline between IFN-β responders and non-responders...
  42. ncbi request reprint Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules
    I Duran
    Unitat de Neuroimmunologia Clinica, Servei de Neurologia, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Brain 122:2297-307. 1999
    ....
  43. ncbi request reprint IFN-beta treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing-remitting multiple sclerosis
    C Espejo
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 10:630-5. 2004
    ..These data support that one of the immunomodulatory effects of IFN-beta treatment in MS may be a limitation of the autoimmune response modifying the CD80:CD28/CTLA-4 pathway...
  44. doi request reprint Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis
    J E Martinez-Rodriguez
    Neurology Service, Parc de Salut Mar, IMIM Hospital del Mar Research Institute, Barcelona, Spain
    Clin Immunol 141:348-56. 2011
    ..Our results reveal that IFNβ may promote in responders changes in the NK cell immunophenotype, corresponding to the profile found at early maturation stages of this lymphocyte lineage...
  45. ncbi request reprint [Listeria rhombencephalitis. Neuroradiological findings]
    I Pericot
    Servei de Neurologia, Unitat de Neuroimmunologia Clinica, Barcelonal, Espana
    Neurologia 18:34-7. 2003
    ..Both patients had a favorable outcome with full clinical recovery. We conclude that MRI aids in the early detection of parenchymal infections, therefore, MRI is crucial for early diagnosis and is very useful for follow-up examinations...
  46. ncbi request reprint Interferons and cognition
    X Montalban
    Unitat de Neuroimmunologia Clinica, Servei de Neurologia, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Neurol Sci 245:137-40. 2006
    ..The data that we have are not conclusive. This paper reviews the effect of IFNbeta on cognition in the different clinical forms of the disease and the future directions of clinical trials...
  47. doi request reprint Treatment with interferon-β does not induce anti-nuclear and anti-neuronal serum autoantibodies in multiple sclerosis patients
    M Comabella
    Servei de Neurologia Neuroimmunologia, Centre d esclerosi multiple de Catalunya, CEM Cat, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    J Neuroimmunol 255:102-4. 2013
    ..Thus, pattern of anti-nuclear and anti-neuronal autoantibodies does not predict the response to IFNβ in MS patients...
  48. doi request reprint IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis
    S Malhotra
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Passeig Vall d Hebron 119 129, Barcelona, Spain
    J Neuroimmunol 239:101-4. 2011
    ..These findings do not support a role of IL28B polymorphisms in the response to IFNβ in MS patients...